Randomized trial · people

Abaloparatide: normal bone biopsies after up to 18 months in ACTIVE

Checked against the paper Randomized trialPublished by PepVault

The takeaway

For abaloparatide users, this adds tissue-level evidence that up to 18 months of treatment in ACTIVE did not raise bone safety concerns in biopsies.

Kind
Randomized trial
Studied in
People
Published
2017
Journal
Bone

What they tested

The team wanted to know how daily abaloparatide shots affect the look and makeup of bone tissue when viewed under a microscope.

How the study was done

A biopsy substudy of the phase 3 ACTIVE randomized trial in people being treated for osteoporosis. Participants got blinded daily shots under the skin of abaloparatide 80μg/d or placebo (a dummy shot), or open-label teriparatide 20μg/d, for 18 months, with hip bone (iliac crest) biopsies taken between months 12 and 18.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking abaloparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Bone samples from the abaloparatide group showed normal bone structure, with no signs of harm to how bone mineralized or to how new layered bone formed. There were no marrow problems, no marrow scarring (fibrosis), and no excess unmineralized bone (osteoid) or disorganized woven bone. Across the three groups, most standard bone tissue measures differed little: eroded surface, a sign of bone breakdown, was lower with abaloparatide than with placebo, while cortical porosity, the amount of space in the outer bone shell, was higher with both abaloparatide and teriparatide than with placebo.

What it doesn’t show

This is a biopsy substudy using bone from one site, the iliac crest, so it speaks to bone tissue under the microscope rather than to fracture risk. The teriparatide comparison group was open-label, not blinded.

The paper

Moreira et al. Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial. Bone. 2017.

The compound

More studies on Abaloparatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking abaloparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo